BMSSC
BEAM icon

B. Metzler seel. Sohn & Co’s Beam Therapeutics BEAM Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,390
Closed -$481K – 726
2022
Q1 		$481K Buy
+8,390
New +$550K 0.01% 601

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

B. Metzler seel. Sohn & Co's BEAM Position: Q2 2022 in Review

B. Metzler seel. Sohn & Co sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 8,390 shares — an estimated $481K sold.

B. Metzler seel. Sohn & Co first reported a position in BEAM in Q1 2022 and held it in 1 quarter. The position peaked at $481K in Q1 2022. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • B. Metzler seel. Sohn & Co reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 8,390 Beam Therapeutics shares in Q2 2022, an estimated $481K.
  • B. Metzler seel. Sohn & Co first reported a position in Beam Therapeutics in Q1 2022 and held it in 1 quarter.
  • B. Metzler seel. Sohn & Co's Beam Therapeutics position peaked at $481K in Q1 2022.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2022, filed 12 Aug 2022.